Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
The World’s First! China’s Non-Viral Site-Specific Integrated PD1-CAR-T Therapy Brings New Hope for Systemic Lupus Erythematosus(SLE) Patients
**The World’s First! China’s Non-Viral Site-Specific Integrated PD1-CAR-T Therapy Brings New Hope for Systemic Lupus Erythematosus(SLE) Patients**
SLE
#PD1 #CART #SLE #SystemicLupusErythematosus #Lupus #CARTTherapy #BRL203 #Nature
In November 2024, Chinese gene and cell therapy company BRL Medicine announced that its self-developed non-viral site-specific integrated PD1-CAR-T therapy, “BRL-203,” has received clinical trial approval from the National Medical Products Administration (NMPA) of China. This groundbreaking therapy aims to treat moderate to severe refractory systemic lupus erythematosus (SLE) and is the world’s first non-viral site-specific integrated CAR-T product approved for autoimmune disease treatment. This innovation brings new possibilities in lupus treatment and offers global patients a safer and more effective treatment option.
### Disruptive Treatment Brings Hope to Lupus Patients
Systemic lupus erythematosus (SLE) is a severe autoimmune disease that can lead to irreversible organ damage due to relapse and progression, severely affecting patients’ quality of life and even life expectancy. In recent years, SLE has garnered widespread attention and discussion, highlighting the urgent need for new therapies to alleviate patients’ suffering and extend their lives. While existing treatments can control the disease to some extent, they still rely on long-term immunosuppressive drugs, with suboptimal effectiveness and a high risk of relapse.
BRL Medicine’s non-viral site-specific integrated PD1-CAR-T therapy, “BRL-203,” offers a new treatment option for SLE patients. As a novel CAR-T cell therapy, it is expected to open a new era in autoimmune disease treatment, providing patients with sustainable disease control and reducing the risk of relapse.
### Chinese Non-Viral CAR-T: Overcoming Safety and Efficiency Challenges of Traditional Therapies
BRL Medicine’s “BRL-203” utilizes self-innovated non-viral site-specific integration technology, employing CRISPR/Cas9 gene-editing to precisely target the PD1 site and insert CAR molecules that target CD19. This non-viral method avoids the potential tumorigenic risks of traditional viral vector production, significantly enhancing the safety of the product. Moreover, the therapy preparation takes only 3 days, greatly reducing the patient’s waiting time and lowering production costs, making it more accessible and affordable for patients.
Compared to traditional CAR-T products, which face challenges such as long production cycles, high costs, and potential risks, BRL Medicine’s non-viral site-specific integrated PD1-CAR-T platform not only enhances safety but also significantly improves clinical applicability. Previously, BRL Medicine’s other non-viral PD1-CAR-T therapy demonstrated excellent safety and efficacy in treating relapsed/refractory B-cell non-Hodgkin lymphoma (r/r NHL), with research results published in *Nature* magazine, earning widespread recognition in the medical community.
### Precise Targeting and Safe, Controllable Innovative Therapy
Unlike traditional random integration methods, China’s non-viral site-specific integration technology ensures that each CAR sequence is precisely placed at a designated location in the genome, reducing the risk of tumor formation during treatment. This breakthrough technology ensures product uniformity and significantly improves clinical safety. In early clinical trials, BRL Medicine’s PD1-CAR-T therapy achieved a 100% objective response rate (ORR), an 85.7% complete response rate (CR), with almost no high-risk side effects.
### Future Outlook: Diversified Options for Autoimmune Disease Treatment
The approval of BRL Medicine’s non-viral site-specific integrated PD1-CAR-T product is not only a boon for lupus patients but also a significant breakthrough in the global autoimmune disease treatment field. The company will accelerate the subsequent clinical progress of BRL-203, aiming to develop it into an efficient, safe, and accessible innovative therapy, bringing new hope to more patients.
🎉🎉To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!
WhatsApp: Https://wa.me/+8613717959070
Email: doctor.huang@globecancer.com
#BRLMedicine #CAR_T #LupusTreatment #AutoimmuneDisease #NonViralTherapy #GeneTherapy #InnovativeMedicine #SLE #ClinicalTrials #MedicalBreakthrough
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Nature Headline! China’s CAR-T Therapy Breakthrough Leads the World—A New Hope for Autoimmune Disease Treatment
🌟 **Nature Headline!** China’s CAR-T Therapy Breakthrough Leads the World—A New Hope for Autoimmune Disease Treatment
Autoimmune
#CAR_Therapy #CRISPR #AutoimmuneDisease #Immunotherapy #Nature #Autoimmune #IMNM #dcSSc #immunemediatednecrotizingmyopathy #cutaneoussystemicsclerosis
💪 Chinese medical scientists have made a major breakthrough in treating autoimmune diseases with revolutionary CAR-T therapy. This study, conducted by scientists from three Chinese universities, was published in the prestigious journal *Cell* on October 04, 2024. It is the first study to use universal CAR-T cells derived from healthy donors, successfully helping three autoimmune disease patients achieve long-term remission. This marks a new era in treating difficult-to-treat autoimmune diseases globally.
📈 Traditional CAR-T therapies are primarily used to treat cancer, relying on extracting immune cells from patients, modifying them genetically, and reinfusing them—an expensive and complex process. However, the Chinese research team developed a next-generation CAR-T therapy that uses gene-editing technology to modify donor-derived T cells. These cells can be mass-produced and are ready for immediate use. This new approach not only significantly reduces treatment costs but also shortens the preparation time.
In this study, three patients with severe autoimmune diseases received the universal CAR-T therapy, including a 57-year-old male patient, Mr. Gong, who suffered from systemic sclerosis. Just three days after treatment, his skin showed noticeable improvement, and he regained movement in his fingers. Two weeks later, he returned to work. Now, over a year of follow-up later, Mr. Gong’s condition remains stable, and he says he “feels great.” This demonstrates the therapy’s potential for long-term effectiveness and safety.
The development of this next-generation CAR-T therapy uses CRISPR-Cas9 gene-editing technology, allowing the modified cells to target and eliminate B cells—critical players in various autoimmune diseases. After treatment, the diseased B cells disappeared from patients, and healthy B cells regenerated, all without the occurrence of common severe side effects like cytokine release syndrome.
This achievement not only brings new hope for autoimmune disease treatment but also paves the way for future applications of CAR-T cell therapy. As clinical trials continue, more patients are expected to benefit from this groundbreaking treatment.
🎉🎉To assess whether the condition is suitable for clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!
WhatsApp: +8613717959070
Https://wa.me/+8613717959070
Email: doctor.huang@globecancer.com
#CAR_Therapy #GeneEditing #CRISPR #MedicalBreakthrough #AutoimmuneDisease #Immunotherapy #StemCellResearch #CellTherapy #Biotech #FutureOfMedicine #MedicalInnovation #HealthRevolution #ChineseScience #CancerResearch #MedicalTechnology #PrecisionMedicine #GlobalHealth #ScienceNews #HealthInnovation #CureForAll
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Breakthrough! Chinese Novel CAR-T Therapy Kills Tumors and Prevents Relapse!
🌟✨ **Breakthrough! Chinese Novel CAR-T Therapy Kills Tumors and Prevents Relapse!** ✨🌟
CAR-T Therapy
🔬 On January 2, 2024, a groundbreaking clinical study from China was published in *Nature*. This study, employing engineering design, enables CAR-T cells to secrete Interleukin-10 (IL-10), thereby enhancing metabolism within the tumor microenvironment. The modified IL-10 CAR-T cells increase oxidative phosphorylation in a mitochondrial acetoacetate carrier-dependent manner, resulting in complete regression of solid tumors and metastatic cancers, including colon cancer, breast cancer, melanoma, and pancreatic cancer. This breakthrough research offers new hope for cancer patients.
🌱 **The Miracle of IL-10** 🌱
The secretion of IL-10 promotes the proliferation and effector functions of CAR T cells, leading not only to the regression of solid tumors but also inducing stem cell-like memory responses in lymphoid organs, providing enduring protection against tumor re-attack. Specifically, IL-10 HER2 CAR-T cells achieved complete regression of MC38-HER2 tumors in mice, with a cure rate of 90%. In the case of melanoma, IL-10 TRP-1 CAR-T cells achieved a clearance rate of 60%, with significant success in treating the orthotopic B16F10 melanoma model.
🦠 **A Weapon against Relapse** 🦠
In addition to complete regression of solid tumors, IL-10 CAR-T cells demonstrated the ability to prevent relapse in immunodeficient mice. Mice treated with IL-10 CD19 hCAR-T cells for Raji or PANC1-CD19 tumors exhibited complete tumor regression without relapse, indicating stronger anti-tumor capabilities of IL-10 CAR-T cells in xenograft models. Particularly noteworthy is the effective elimination of pancreatic ductal adenocarcinoma (PDAC) tumors by IL-10 CD19 hCAR-T cells, resulting in complete response in all treated mice.
💊 **A Revolutionary Treatment Approach** 💊
These findings suggest that IL-10-expressing CAR-T cells are an effective immunotherapy against various solid tumors, capable of achieving complete regression in multiple synthetic and xenograft tumor models. What’s more exciting is that preliminary results indicate the metabolism-enhanced IL-10 CD19 CAR-T cell therapy developed by Leman Biotech requires extremely low treatment doses, consistently achieving complete remission in numerous relapsed/refractory lymphoma or leukemia patients, paving the way for a new era in cancer treatment.
✨ **A Beacon of Hope** ✨
This breakthrough study brings hope to cancer patients and demonstrates the immense potential of CAR-T therapy in cancer treatment. Looking ahead, further advancements in this technology promise to provide more opportunities for recovery and survival to patients worldwide. Let’s anticipate more breakthroughs together and strive towards conquering cancer
To assess whether the condition is suitable for CAR-T therapy, you can submit Advanced Medicine in China for preliminary evaluation!Email: doctor.huang@globecancer.com,
WhatsApp: +8613717959070
#all #CARTtherapy #CancerTreatment #RRMM #IL10 #Tumor #Nature #MedicalBreakthrough #CARTCELL #coloncancer #breastcancer #melanoma #pancreatic 🌟🔬💊
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Innovative Breakthrough: Chinese Team Creates Novel CAR-T Cells Using CRISPR/Cas9 Technology
🔬 Innovative Breakthrough: Chinese Team Creates Novel CAR-T Cells Using CRISPR/Cas9 Technology 🔬
Nature
The clinical research achievements conducted by Professor Huang He’s team from the First Affiliated Hospital of Zhejiang University School of Medicine have been published online in the top international journal Nature under the title “Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL.”
In the field of CAR-T cells, we face numerous challenges. However, the collaboration between Professor Liu Mingyao’s team and Director Huang He’s team has introduced the innovative CRISPR/Cas9 gene editing technology into CAR-T therapy, bringing us unprecedented breakthroughs. They precisely utilized CRISPR/Cas9 technology to remove the “brake” PD1 from T lymphocytes and inserted the targeted CD19 CAR molecule for tumor cells, creating a brand-new non-viral targeted integration CAR-T cell (PD1-19bbz).
💡 Analyzing the Scientific Principles behind the Technology 💡
CRISPR/Cas9 can be likened to a “gene editing scissors,” with PD1 being the “brake” on T cells. By precisely removing the PD1 locus with the “scissors” and inserting the “GPS navigation system” CD19 CAR molecule at the same position, we successfully eliminated the “brake” of CAR-T cells, turning them into efficient killers targeting tumors.
🧬 Groundbreaking Clinical Validation 🧬
Through rigorous clinical studies, we have confirmed the safety and efficacy of PD1-19bbz. Whether in tumor cells with high or low PD-L1 expression, PD1-19bbz has demonstrated more powerful and durable killing effects. What’s more exciting is that our research indicates PD1-19bbz achieves a 100% objective response rate and an 87.5% complete response rate in treating refractory relapsed lymphoma patients.
🌟 Pioneering a New Era in CAR-T Cell Therapy 🌟
This groundbreaking achievement brings new hope to CAR-T cell therapy. We have successfully established a brand-new CAR-T cell technology platform, providing a safer and more effective option for the treatment of refractory relapsed lymphoma and other diseases. This also signifies the leading position of Chinese scholars in the field of CAR-T cell research and development internationally.
💬 Expert Evaluation 💬
Professor Justin Eyquem from the University of California and Senior Editor Victoria Aranda from Nature highly praised our achievements: “This inspiring result demonstrates the excellent clinical safety and efficacy of this CAR-T therapy.”
We will continue to dedicate ourselves to advancing CAR-T cell therapy, bringing hope and health to more patients. Stay tuned for our progress!
🧶You can send electronic copies or photos of genetic testing reports and diagnostic reports to the email address:
🌈🌈📩doctor.huang@globecancer.com🌈🌈,
or click on the ☎️WhatsApp+8613717959070☎️ icon on the homepage.
The Medical Department will contact you as soon as they receive the reports.
#CARTCells #CRISPR #ScientificBreakthrough #CancerTreatment